三阴性乳腺癌中细胞分裂蛋白调节因子1的表达及新辅助化疗对其表达的影响  

The expression of PRC1 in triple-negative breast cancer and the impact of neoadjuvant chemotherapy on its expression

作　　者：金晓霞 刘玉山[1] 陈鑫焱 徐强 於海燕 李春笋[1] JIN Xiaoxia;LIU Yushan;CHEN Xinyan;XU Qiang;YU Haiyan;LI Chunsun(Department of Pathology,Affiliated Tumor Hospital of Nantong University,Nantong,Jiangsu 226000,China;Medical College of Nantong University,Nantong,Jiangsu 226000,China)

机构地区：[1]南通大学附属肿瘤医院病理科,江苏南通226000 [2]南通大学医学院,江苏南通226000

出　　处：《安徽医药》2024年第12期2488-2491,I0010,共5页Anhui Medical and Pharmaceutical Journal

基　　金：南通市科技计划指令性项目(MS22022015)。

摘　　要：目的探讨细胞分裂蛋白调节因子1(PRC1)在三阴性乳腺癌(TNBC)组织中的表达及新辅助化疗对其表达的影响。方法回顾性收集南通大学附属肿瘤医院病理科2010-2018年存档的、经过手术的乳腺癌病人组织,利用免疫组织化学EnVision法检测PRC1在55例正常乳腺组织、49例腔面型乳腺癌、40例人表皮生长因子受体2(HER-2)过表达型乳腺癌及40例TNBC样本中的表达,比较各组别中PRC1的表达差异。统计分析PRC1的表达水平与TNBC临床病理参数之间的相关性。比较TNBC新辅助化疗前后PRC1的表达变化。结果PRC1在正常乳腺组织、腔面型乳腺癌、HER-2过表达型乳腺癌、TNBC中的阳性表达率分别为7.27%(4/55)、30.61%(15/49)、32.50%(13/40)和95.00%(38/40)。PRC1在TNBC中的阳性表达率显著高于其他类型(P<0.017),并且与脉管侵犯和淋巴结转移具有正相关性(P<0.05)。新辅助化疗后,TNBC中PRC1的表达明显下降,降为52.50%(21/40)。结论PRC1在TNBC中的表达明显高于其他类型乳腺癌,并与其脉管侵犯、淋巴结转移呈正相关,新辅助化疗可以显著降低PRC1的表达。因此,PRC1有望成为TNBC诊断和防治的新靶点。Objective To explore the expression of protein regulator of cytokinesis 1(PRC1)in triple-negative breast cancer(TNBC)tissues,and the effect of neoadjuvant chemotherapy on its expression.Methods Tissues of breast cancer patients undergoing surgery,archived in Department of Pathology,Affiliated Cancer Hospital of Nantong University from 2010 to 2018,were retrospectively collected.The expressions of PRC1 in 55 normal breast tissue,49 cases of luminal type breast cancer,40 cases of human epidermal growth factor receptor 2(HER-2)overexpressing breast cancer and 40 TNBC samples were detected by an immunohistochemical staining technique the EnVision method,and the differences in PRC1 expression between groups were compared.The correlation between the expression level of PRC1 and the clinicopathological parameters of TNBC was statistically analyzed,and the changes of PRC1 expression before and after neoadjuvant chemotherapy in TNBC were compared.Results The positive expression rates of PRC1 in normal breast tissue,luminal type breast cancer,HER-2 overexpressing breast cancer,and TNBC were 7.27%(4/55),30.61%(15/49),32.50%(13/40),and 95.00%(38/40).The positive expression rate of PRC1 in TNBC was significantly higher than that in other types(P<0.017),and positively correlated with vascular invasion and lymph node metastasis(P<0.05).After neoadjuvant chemotherapy for TNBC,the expression of PRC1 was significantly reduced,with a positive expression rate dropping to 52.50%(21/40).Conclusions The expression of PRC1 in TNBC was significantly higher than that in other types of breast cancer and had a positive correlation with its vascular invasion and lymph node metastasis,and neoadjuvant chemotherapy significantly reduced the expression of PRC1.Therefore,PRC1 is expected to be a new target for the diagnosis and prevention of TNBC.

关 键 词：三阴性乳腺癌 细胞分裂蛋白调节因子1 新辅助化疗 免疫组织化学 临床病理特征 

分 类 号：R737.9[医药卫生—肿瘤]